A Trial of Finerenone in a Patient with Primary Aldosteronism
Introduction: Primary aldosteronism (PA), a common secondary cause of arterial hypertension, is treated either surgically or pharmacologically with mineralocorticoid receptor antagonists (MRAs). These drugs, while effective, can cause allergic reactions and have side effects, including menstrual cyc...
Gardado en:
Autor Principal: | Sandra Karanović Štambuk (Author) |
---|---|
Formato: | Libro |
Publicado: |
Karger Publishers,
2024-09-01T00:00:00Z.
|
Subjects: | |
Acceso en liña: | Connect to this object online. |
Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|
Títulos similares
-
Baxdrostat and finerenone: new aldosterone synthase-aldosterone-mineralocorticoid receptor hormonal system inhibitors for the drug treatment of resistant arterial hypertension
por: O. B. Kuzmin, et al.
Publicado: (2024) -
Administration of finerenone in chronic kidney disease
por: Mohsen Akhavan Sepahi, et al.
Publicado: (2023) -
Residual Renal Function: A Double-Edged Sword
por: Sandra Karanović Štambuk, et al.
Publicado: (2024) -
A case of primary aldosteronism
por: Stephanie Zilberman, et al.
Publicado: (2022) -
Primary Aldosteronism and Pregnancy
por: Tomáš Zelinka, et al.
Publicado: (2020)